JP2015078226A - 抗菌ペプチドおよびタンパク質のレベルの上昇に関連する皮膚の疾患または障害を処置または緩和するための組成物 - Google Patents
抗菌ペプチドおよびタンパク質のレベルの上昇に関連する皮膚の疾患または障害を処置または緩和するための組成物 Download PDFInfo
- Publication number
- JP2015078226A JP2015078226A JP2014263552A JP2014263552A JP2015078226A JP 2015078226 A JP2015078226 A JP 2015078226A JP 2014263552 A JP2014263552 A JP 2014263552A JP 2014263552 A JP2014263552 A JP 2014263552A JP 2015078226 A JP2015078226 A JP 2015078226A
- Authority
- JP
- Japan
- Prior art keywords
- tambrissa
- skin
- extract
- plant extract
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 238000011282 treatment Methods 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 17
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims abstract description 14
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims abstract description 14
- 208000017520 skin disease Diseases 0.000 title claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 50
- 239000000284 extract Substances 0.000 claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 48
- 239000000419 plant extract Substances 0.000 claims abstract description 47
- 208000035475 disorder Diseases 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 21
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 18
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 18
- 241000196324 Embryophyta Species 0.000 claims abstract description 16
- 230000000699 topical effect Effects 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 12
- 241000894007 species Species 0.000 claims abstract description 7
- 210000003491 skin Anatomy 0.000 claims description 44
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims description 25
- 206010015150 Erythema Diseases 0.000 claims description 22
- 108060001132 cathelicidin Proteins 0.000 claims description 22
- 102000014509 cathelicidin Human genes 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 201000004700 rosacea Diseases 0.000 claims description 19
- 241001303601 Rosacea Species 0.000 claims description 15
- 230000004054 inflammatory process Effects 0.000 claims description 15
- 206010061218 Inflammation Diseases 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 201000004681 Psoriasis Diseases 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 9
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 206010043189 Telangiectasia Diseases 0.000 claims description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 208000009056 telangiectasis Diseases 0.000 claims description 9
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims description 8
- 230000033228 biological regulation Effects 0.000 claims description 8
- 231100000321 erythema Toxicity 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 206010000349 Acanthosis Diseases 0.000 claims description 7
- 208000010201 Exanthema Diseases 0.000 claims description 7
- 108060005987 Kallikrein Proteins 0.000 claims description 7
- 102000001399 Kallikrein Human genes 0.000 claims description 7
- 201000005884 exanthem Diseases 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 206010037844 rash Diseases 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 208000001840 Dandruff Diseases 0.000 claims description 6
- 230000033115 angiogenesis Effects 0.000 claims description 6
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 208000037976 chronic inflammation Diseases 0.000 claims description 6
- 230000007794 irritation Effects 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 210000004761 scalp Anatomy 0.000 claims description 6
- 230000006020 chronic inflammation Effects 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 230000002491 angiogenic effect Effects 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 102100040312 Ribonuclease 7 Human genes 0.000 claims description 3
- 108010085025 Ribonuclease 7 Proteins 0.000 claims description 3
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 claims description 3
- 208000038016 acute inflammation Diseases 0.000 claims description 3
- 230000006022 acute inflammation Effects 0.000 claims description 3
- 102000018568 alpha-Defensin Human genes 0.000 claims description 3
- 108050007802 alpha-defensin Proteins 0.000 claims description 3
- 102000012265 beta-defensin Human genes 0.000 claims description 3
- 108050002883 beta-defensin Proteins 0.000 claims description 3
- 230000013632 homeostatic process Effects 0.000 claims description 3
- 230000007803 itching Effects 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 claims 1
- 230000003527 anti-angiogenesis Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 241000909582 Tambourissa Species 0.000 abstract description 11
- 230000008569 process Effects 0.000 abstract description 3
- 208000034493 Mucous membrane disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 23
- 230000000694 effects Effects 0.000 description 17
- 238000009472 formulation Methods 0.000 description 16
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 13
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 13
- 229960004555 rutoside Drugs 0.000 description 13
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 12
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 12
- 235000005493 rutin Nutrition 0.000 description 12
- 102000013691 Interleukin-17 Human genes 0.000 description 10
- 108050003558 Interleukin-17 Proteins 0.000 description 10
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 9
- 150000002215 flavonoids Chemical class 0.000 description 9
- 235000017173 flavonoids Nutrition 0.000 description 9
- RTATXGUCZHCSNG-ZFDPGQBLSA-N nicotiflorin Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RTATXGUCZHCSNG-ZFDPGQBLSA-N 0.000 description 9
- RTATXGUCZHCSNG-UHFFFAOYSA-N nicotiflorine Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-UHFFFAOYSA-N 0.000 description 9
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 8
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 8
- RTATXGUCZHCSNG-QHWHWDPRSA-N Nicotiflorin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-QHWHWDPRSA-N 0.000 description 8
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 8
- 235000012734 epicatechin Nutrition 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002870 angiogenesis inducing agent Substances 0.000 description 7
- -1 iron ion Chemical class 0.000 description 7
- 230000004089 microcirculation Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 101710140438 Cathelicidin antimicrobial peptide Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 5
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229960005084 calcitriol Drugs 0.000 description 4
- 235000020964 calcitriol Nutrition 0.000 description 4
- 239000011612 calcitriol Substances 0.000 description 4
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229960000282 metronidazole Drugs 0.000 description 4
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 235000005282 vitamin D3 Nutrition 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 229940021056 vitamin d3 Drugs 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 125000003345 AMP group Chemical group 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 2
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 2
- 244000020518 Carthamus tinctorius Species 0.000 description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 241001501807 Centaurea hierapolitana Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 102100034868 Kallikrein-5 Human genes 0.000 description 2
- 102100034867 Kallikrein-7 Human genes 0.000 description 2
- 102000003820 Lipoxygenases Human genes 0.000 description 2
- 108090000128 Lipoxygenases Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 102100032446 Protein S100-A7 Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960002255 azelaic acid Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920001461 hydrolysable tannin Polymers 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229930015704 phenylpropanoid Natural products 0.000 description 2
- 125000001474 phenylpropanoid group Chemical group 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 230000001185 psoriatic effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 108700022109 ropocamptide Proteins 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229960000551 sulfacetamide sodium Drugs 0.000 description 2
- IHCDKJZZFOUARO-UHFFFAOYSA-M sulfacetamide sodium Chemical compound O.[Na+].CC(=O)[N-]S(=O)(=O)C1=CC=C(N)C=C1 IHCDKJZZFOUARO-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- LKZDFKLGDGSGEO-UHFFFAOYSA-N 2',8-Di-Me ether,7-O-beta-D-glucuronoside-2',5,7,8-Tetrahydroxyflavone Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)OC(CO)C(O)C1O LKZDFKLGDGSGEO-UHFFFAOYSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001091379 Homo sapiens Kallikrein-5 Proteins 0.000 description 1
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- RTATXGUCZHCSNG-TYSPDFDMSA-N Kaempferol-3-O-rutinoside Natural products OC1[C@H](O)[C@@H](O)C(C)O[C@H]1OCC1[C@@H](O)[C@@H](O)C(O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=CC(O)=CC=2)=O)O1 RTATXGUCZHCSNG-TYSPDFDMSA-N 0.000 description 1
- 101710176223 Kallikrein-5 Proteins 0.000 description 1
- 101710176222 Kallikrein-7 Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- 244000235756 Microcos paniculata Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241001621828 Monimia Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241001431534 Pogonatherum crinitum Species 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 241000963807 Tambourissa religiosa Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229940122407 Vitamin D antagonist Drugs 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- KQNZLOUWXSAZGD-UHFFFAOYSA-N benzylperoxymethylbenzene Chemical compound C=1C=CC=CC=1COOCC1=CC=CC=C1 KQNZLOUWXSAZGD-UHFFFAOYSA-N 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 101150099961 camP gene Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 235000021038 drupes Nutrition 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960003808 nadifloxacin Drugs 0.000 description 1
- JYJTVFIEFKZWCJ-UHFFFAOYSA-N nadifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)CCC3=C1N1CCC(O)CC1 JYJTVFIEFKZWCJ-UHFFFAOYSA-N 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940030793 psoriasin Drugs 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- VVXVTYYCCQZUKK-UHFFFAOYSA-N quercetin 3-rutinoside Natural products CC1OC(OCC2OC(OC3=C(Oc4ccc(O)c(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C(O)C2O)C(O)C(O)C1O VVXVTYYCCQZUKK-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000006884 regulation of angiogenesis Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- OVVGHDNPYGTYIT-BNXXONSGSA-N rutinose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 OVVGHDNPYGTYIT-BNXXONSGSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008275 solid aerosol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- JLVSPVFPBBFMBE-HXSWCURESA-O sphingosylphosphocholine acid Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H]([NH3+])COP([O-])(=O)OCC[N+](C)(C)C JLVSPVFPBBFMBE-HXSWCURESA-O 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/002—Aftershave preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】タンブリッサ植物抽出物を含む皮膚病の処置用の局所用医薬または局所用美容用組成物であって、植物が、タンブリッサ・ミクロフィラ、タンブリッサ・レリギオーサ、タンブリッサ・カプロニーまたはタンブリッサ・トリコフィラの種から選択され、タンブリッサ・トリコフィラ植物抽出物が植物の葉の抽出物である、局所用医薬または局所用美容用組成物。
【選択図】なし
Description
−抗菌ペプチド(カテリシジン類)および関連酵素の活性型の過剰発現、これは、皮膚の慢性炎症を導くか、または、皮膚炎症の慢性を利する感染状態の維持に関与する
−頻繁な出血の特徴を伴う毛細血管の血管新生の障害に寄与する血管の異常、これは、自然に薄く反応性になりがちな皮膚の虚弱化を導く、
−最初はわかりにくいが、着実に増大し、紅潮および発赤の現象を伴って持続化する炎症、
−UVまたはフリーラジカルなどの環境要因に依存する炎症過程。
本発明による医薬または美容用組成物に含まれるポリフェノール類は、元々は植物で発見された、分子1個につき1個より多いフェノールユニットまたは構成要素の存在を特徴とする化学物質の一群である。ポリフェノール類は、一般的に、加水分解性のタンニン類(グルコースおよび他の糖の没食子酸エステル)およびフェニルプロパノイド類に分類され、例えば、リグニン類、フラボノイド類および縮合型タンニンがある。本発明による好ましいポリフェノール類はフラボノイド類であり、特に好ましいポリフェノール類は、ルチン、ニコチフロリンおよび/またはエピカテキンである。
慢性炎症として知られる長期の炎症は、炎症部位に存在する細胞のタイプの連続的な変化を導き、分解不可能な病原体、持続性の異物または自己免疫反応に起因する急性炎症の持続のために、炎症過程からの組織の破壊と治癒が同時に起こることを特徴とする。自己免疫反応は、リンパ球の関与およびそれらのTh1、Th2および/またはTh17への様々なインデューサーへ向かう特異的分化に関連付けることができ、いくつかの特定のメディエーター、インターロイキン−1(IL−1)、IL−4およびIL−17の特異的強調を導く。乾癬は、Th17/Th1の混合型疾患であると考えられ、一方、アトピー性皮膚炎は、Th17/Th2の混合型疾患であると考えられる。
本発明の目的は、また、上記の美容用組成物による、AMPレベルの上昇に関連する障害の美容的処置方法である。
本発明のもう1つの目的は、タンブリッサ植物抽出物、好ましくはタンブリッサ・トリコフィラの植物抽出物、特に好ましくはタンブリッサ・トリコフィラの葉の抽出物による、AMPレベルの上昇に関連する疾患または障害、特に皮膚または粘膜の疾患または障害の処置方法である。
抽出は、植物の全体で実施できる。好ましくは、タンブリッサ・トリコフィラの葉を抽出する。
a. 水とアルコールの極性溶媒混合物による葉の抽出、
b. アルコールの除去および濾過
c. 得られた極性溶液の非極性溶媒による抽出。
本発明による抽出物は、通常、乾燥抽出物である。それにも拘わらず、抽出物は溶液としても使用できる。即ち、記載した抽出方法の最後の乾燥段階を省略するか、または、例えば、他の活性化合物と混合するか、カプセル封入のように、最適化された担体に導入することにより、さらに進める。
以下の実施例は、本発明をその全般的性質において限定せずに、本発明の実施態様を例示説明する。
実施例1:抽出方法
破砕したタンブリッサ・トリコフィラの乾燥葉を、エタノールと水の70:30の混合物で抽出する。溶液を撹拌し、抽出段階中に60℃より低い温度で、30分間ないし1時間加熱する。植物の除去後、エタノールを除去し、沈殿を導き、それを濾過する。次いで、残っている水性溶液を、酢酸エチルでの液体−液体抽出により処理する。酢酸画分を酢酸蒸留のために保持し、結果として生じる水性溶液を凍結乾燥する。
表1:様々な濃度の実施例1によるタンブリッサ・トリコフィラの葉の抽出物を含有する乳液
HUVEC(ヒト臍帯静脈内皮細胞)で試験を実施した。
HUVECを、実施例1による抽出物なしで(対照)、または、様々な濃度の実施例1による抽出物と共に、そして、インデューサー:VEGF(血管内皮増殖因子)の存在下で、24時間インキュベートした。媒体中のPGE−2レベルをELISA法により測定した。有意性をステューデント検定により評価した。
本発明による抽出物が抗菌ペプチドカテリシジンの放出を阻害する能力を調べた。hCAP18(さらにLL37に活性化される)をコードするCAMP(カテリシジン抗菌ペプチド)遺伝子の発現を、角化細胞NHEK(074)から抽出したmRNAにRT−qPCR技法を使用して実施した。
アッセイ培地:ゲンタマイシン25μg/ml(Sigma G1397)を添加した角化細胞−SFM(Invitrogen 17005075)。
本発明に従って得られた抽出物をDMSOに可溶化し、0.05、0.5および5μg/mlで試験した。
−サーモサイクラー:迅速なPCR適用に最適化されている;反応混合物内の極度に迅速な熱移動を可能にする。
−蛍光光度計:インターカレートする染料である SYBR Green I;伸長サイクル中に二本鎖DNAに特異的に結合する染料(検出波長:521nm)の不断の蛍光測定を可能にする。
この実験では、肝臓グリセルアルデヒド3−リン酸脱水素酵素遺伝子(G3PDH)を参照マーカーとして使用した。
増幅されたDNAにおける蛍光の組込みを、PCRサイクル中に継続的に測定した。
実施例1による抽出物(タンブリッサ・トリコフィラの葉の抽出物または「アンボラ」)は、LL37をコードするカテリシジン遺伝子を用量依存的に減少させる。この減少は、IL−17誘導の場合40%(誘導ありの対照と比較)に、カルシトリオール誘導で27%に達し得た。
この研究の目的は、様々な濃度の本発明による抽出物を含有する組成物の効力を評価することであった。試験は、各々0.3%および0.5%の抽出物を含有する2つの製剤で実施した(実施例2による製剤BおよびC)。この試験は、対プラセボで実施した(実施例2による製剤A)。
皮膚科医の制御下にあるこの研究の条件下で、1日2回の28日間または56日間の使用後に、全ての製剤の皮膚耐容性は良好であった。
表4:試験製品の1日2回、28日間および56日間の使用後の皮膚科医によるスコア付けの変動(初期条件との比較):
熱伝導度の低下は、皮膚の微小循環の低下(血管収縮)に相当し、それは、抗酒さ効果に寄与するであろう。
表5:試験製品の1日2回、28日間および56日間の使用後の熱伝導度の変動(初期条件との比較):
プラセボでも0.3%製剤のD56でも、有意な変動は観察されなかった。
皮膚の発赤および皮膚の微小循環の減少は、製剤BおよびC(本発明によるタンブリッサ植物抽出物を含む医薬または美容用組成物の候補)を、酒さ、紅皮症、毛細血管拡張症または皮膚の発赤/染みの処置および/または緩和に適するものにする。
本発明による抽出物の活性を、ヒトの角化細胞による血管新生促進因子の発現に関して研究した。タンブリッサ抽出物(5μg/ml)の活性を、以下のインデューサーで刺激した角化細胞NHEK K(074)から抽出したRNAに対するRT−q−PCR技術により試験した:LL−37(20μg/ml)、IL−17(10ng/ml)、ビタミンD3(10−6M)およびこれらの組合せ。
REの計算のために選択される値は、蛍光曲線の「出力点」(Ct)である。ある考慮されるマーカーについて、最高はサイクル数である;最低はmRNA量である。
アッセイ培地:ゲンタマイシン25μg/mlを添加した角化細胞−SFM
効果の分類(「処置」対「対照」条件):解釈の標準化のために、下表を提案する:
Claims (12)
- タンブリッサ植物抽出物を含む皮膚病の処置用の局所用医薬であって、植物が、タンブリッサ・ミクロフィラ、タンブリッサ・レリギオーサ、タンブリッサ・カプロニーまたはタンブリッサ・トリコフィラの種から選択され、タンブリッサ・トリコフィラ植物抽出物が植物の葉の抽出物である、局所用医薬。
- 皮膚病が、酒さ、クーペロシス、紅皮症、毛細血管拡張症、疱疹、乳児の発疹、フケ、皮膚の発赤、皮膚の染み、アトピー性皮膚炎、乾癬、アカントーシス、日光紅斑、ひげそり後の刺激またはそう痒である、請求項1に記載の局所用医薬。
- タンブリッサ植物抽出物が0.01ないし10重量%の量で存在する、請求項1に記載の植物抽出物を含む局所用医薬。
- タンブリッサ植物抽出物が、抗菌ペプチドまたはタンパク質、特にα−またはβ−デフェンシン、RNase−7、S100−タンパク質プソリアシンまたはカテリシジンおよび/またはカリクレインを調節する、請求項1ないし請求項3のいずれかに記載の局所用医薬。
- 抗炎症活性を有し、かつ/または、急性または慢性炎症における免疫応答を調節し、上皮、皮膚、頭皮または粘膜組織の恒常性を調節し、かつ/または、血管新生を調節する、請求項1ないし請求項4のいずれかに記載の局所用医薬。
- タンブリッサ・ミクロフィラ、タンブリッサ・レリギオーサ、タンブリッサ・カプロニーまたはタンブリッサ・トリコフィラの種から選択されるタンブリッサ植物抽出物を含む局所用美容用組成物であって、タンブリッサ・トリコフィラ植物抽出物が植物の葉の抽出物である、局所用美容用組成物。
- 抗菌ペプチドまたはタンパク質を調節し、抗炎症活性を有し、かつ/または、急性または慢性炎症における免疫応答を調節し、皮膚、頭皮または粘膜組織の恒常性を調節し、かつ/または、血管新生を調節する、請求項6に記載の局所用美容用組成物。
- 酒さ、クーペロシス、紅皮症、毛細血管拡張症、疱疹、乳児の発疹、フケ、皮膚の発赤、皮膚の染み、アトピー性皮膚炎、乾癬、アカントーシス、日光紅斑、ひげそり後の刺激またはそう痒に関連する皮膚の障害を緩和するための、請求項6に記載の局所用美容用組成物。
- a.水とアルコールの極性溶媒混合物による葉の抽出、
b.アルコールの除去および濾過、
c.得られた極性溶液の非極性溶媒による抽出、
の各段階を含む、タンブリッサ・トリコフィラの葉の抽出物の製造方法。 - ポリフェノール含有量が10ないし100%である、請求項9に記載の方法に従って得られる植物抽出物。
- 抗菌ペプチドまたはタンパク質の調節における、特にカテリシジンおよび/またはカリクレイン合成の阻害および/または低減における、かつ/または、抗炎症剤および/または血管新生調節物質としての、タンブリッサ植物抽出物の使用であって、植物が、タンブリッサ・ミクロフィラ、タンブリッサ・レリギオーサまたはタンブリッサ・カプロニーの種から選択されるか、または、植物抽出物がタンブリッサ・トリコフィラの葉の植物抽出物である、タンブリッサ植物抽出物の使用。
- 抗菌ペプチドまたはタンパク質のレベルの上昇に関連する皮膚の疾患または障害、炎症および/または血管新生障害の処置用のタンブリッサ植物抽出物であって、植物が、タンブリッサ・ミクロフィラ、タンブリッサ・レリギオーサまたはタンブリッサ・カプロニーの種から選択されるか、または、植物抽出物がタンブリッサ・トリコフィラの葉の植物抽出物である、タンブリッサ植物抽出物。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290925 | 2008-10-02 | ||
EP08290925.0 | 2008-10-02 | ||
EP09290027 | 2009-01-13 | ||
EP09290027.3 | 2009-01-13 | ||
EP09290332 | 2009-05-07 | ||
EP09290332.7 | 2009-05-07 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011529477A Division JP5714494B2 (ja) | 2008-10-02 | 2009-10-01 | 抗菌ペプチドおよびタンパク質のレベルの上昇に関連する皮膚の疾患または障害を処置または緩和するための組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2015078226A true JP2015078226A (ja) | 2015-04-23 |
Family
ID=41395939
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011529477A Active JP5714494B2 (ja) | 2008-10-02 | 2009-10-01 | 抗菌ペプチドおよびタンパク質のレベルの上昇に関連する皮膚の疾患または障害を処置または緩和するための組成物 |
JP2014263552A Pending JP2015078226A (ja) | 2008-10-02 | 2014-12-25 | 抗菌ペプチドおよびタンパク質のレベルの上昇に関連する皮膚の疾患または障害を処置または緩和するための組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011529477A Active JP5714494B2 (ja) | 2008-10-02 | 2009-10-01 | 抗菌ペプチドおよびタンパク質のレベルの上昇に関連する皮膚の疾患または障害を処置または緩和するための組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20120009290A1 (ja) |
EP (1) | EP2331209A1 (ja) |
JP (2) | JP5714494B2 (ja) |
KR (2) | KR20170048606A (ja) |
CA (1) | CA2739001C (ja) |
WO (1) | WO2010037545A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180094915A (ko) * | 2015-12-22 | 2018-08-24 | 장-노엘 또렐 | 건선, 아토피성 피부염, 만성 두드러기, 항히스타민-내성 가려움증 및 노인성 가려움증의 치료를 위한 암보라 추출물 및 녹차 추출물을 포함하는 조성물 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
US9526689B2 (en) | 2011-12-09 | 2016-12-27 | Mary Kay Inc. | Skin care formulation |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
CN105026930B (zh) * | 2013-03-15 | 2018-06-12 | 宝洁公司 | 用于测量来自皮肤的抗微生物肽作为对微生物天然防护的客观量度的非侵入性方法 |
JP6393524B2 (ja) * | 2014-06-05 | 2018-09-19 | ロート製薬株式会社 | 保湿剤 |
CN110573141A (zh) * | 2017-04-28 | 2019-12-13 | 西姆莱斯有限公司 | 欧蓍草鲜榨植物汁浓缩物、制造和应用 |
CN112370387B (zh) * | 2020-11-03 | 2022-01-14 | 珀莱雅化妆品股份有限公司 | 一种具有头皮护理功效的植物双向发酵物的制备方法及其应用 |
US20230001326A1 (en) * | 2021-07-02 | 2023-01-05 | Winters Capital IP LLC | Process for extracting bioactive compounds from plant materials |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07188031A (ja) * | 1993-10-15 | 1995-07-25 | Bristol Myers Squibb Co | 皮膚損傷の治療に使用する治療用組成物およびその製造方法 |
WO2005077349A1 (ja) * | 2004-02-17 | 2005-08-25 | Otsuka Pharmaceutical Co., Ltd. | ヒトβディフェンシン産生促進剤 |
JP2007186457A (ja) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | トリプターゼ活性阻害剤およびその利用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5944313A (ja) * | 1982-09-07 | 1984-03-12 | Yakult Honsha Co Ltd | 抗菌性組成物 |
JPS60208908A (ja) * | 1984-03-31 | 1985-10-21 | Kanebo Ltd | 日焼け防止化粧料 |
US7314634B2 (en) * | 2002-02-22 | 2008-01-01 | Steven Hernandez | Use of polyphenols to treat skin conditions |
-
2009
- 2009-10-01 WO PCT/EP2009/007051 patent/WO2010037545A1/en active Application Filing
- 2009-10-01 CA CA2739001A patent/CA2739001C/en active Active
- 2009-10-01 KR KR1020177010970A patent/KR20170048606A/ko not_active Application Discontinuation
- 2009-10-01 KR KR1020117007574A patent/KR20110074857A/ko active Application Filing
- 2009-10-01 EP EP09736825A patent/EP2331209A1/en not_active Withdrawn
- 2009-10-01 JP JP2011529477A patent/JP5714494B2/ja active Active
-
2011
- 2011-04-04 US US13/065,996 patent/US20120009290A1/en not_active Abandoned
-
2012
- 2012-11-11 US US13/674,060 patent/US9114115B2/en not_active Expired - Fee Related
-
2014
- 2014-12-25 JP JP2014263552A patent/JP2015078226A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07188031A (ja) * | 1993-10-15 | 1995-07-25 | Bristol Myers Squibb Co | 皮膚損傷の治療に使用する治療用組成物およびその製造方法 |
WO2005077349A1 (ja) * | 2004-02-17 | 2005-08-25 | Otsuka Pharmaceutical Co., Ltd. | ヒトβディフェンシン産生促進剤 |
JP2007186457A (ja) * | 2006-01-13 | 2007-07-26 | Ichimaru Pharcos Co Ltd | トリプターゼ活性阻害剤およびその利用 |
Non-Patent Citations (4)
Title |
---|
ANONYMOUS, NEW DECLEOR VITAROMA LIFT TOTAL NECK & DECOLLETE GEL-CREAM, JPN6015046558, 2007, ISSN: 0003199301 * |
LHUILLIER A.: "3.Etude phytochimique des feuilles de Tambourissa trichophyla(TTI)", L'IINSTITUT NSTIONAL POLYTECHNIQUE DE TOULOUSE, JPN6014000956, 2007, pages 98 - 113, ISSN: 0003199302 * |
PLANTES MEDICINALES DE MAURICE, vol. 1864年, JPN6014000961, pages 124, ISSN: 0003199300 * |
PLANTES MEDICINALES ET PHYTOTHERAPIE, vol. 15, no. 2, JPN6015046559, 1981, pages 80 - 91, ISSN: 0003199303 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180094915A (ko) * | 2015-12-22 | 2018-08-24 | 장-노엘 또렐 | 건선, 아토피성 피부염, 만성 두드러기, 항히스타민-내성 가려움증 및 노인성 가려움증의 치료를 위한 암보라 추출물 및 녹차 추출물을 포함하는 조성물 |
KR102623994B1 (ko) | 2015-12-22 | 2024-01-11 | 장-노엘 또렐 | 건선, 아토피성 피부염, 만성 두드러기, 항히스타민-내성 가려움증 및 노인성 가려움증의 치료를 위한 암보라 추출물 및 녹차 추출물을 포함하는 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CA2739001A1 (en) | 2010-04-08 |
JP2012504564A (ja) | 2012-02-23 |
JP5714494B2 (ja) | 2015-05-07 |
WO2010037545A1 (en) | 2010-04-08 |
US9114115B2 (en) | 2015-08-25 |
CA2739001C (en) | 2018-07-24 |
KR20170048606A (ko) | 2017-05-08 |
EP2331209A1 (en) | 2011-06-15 |
KR20110074857A (ko) | 2011-07-04 |
US20130071502A1 (en) | 2013-03-21 |
US20120009290A1 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5714494B2 (ja) | 抗菌ペプチドおよびタンパク質のレベルの上昇に関連する皮膚の疾患または障害を処置または緩和するための組成物 | |
KR102257524B1 (ko) | 피부 진정 및 재생효과를 지니는 병풀 유래 엑소좀 함유 피부 개선용 화장료 조성물 | |
US7642062B2 (en) | Compositions and methods of their use for improving the condition and appearance of skin | |
Avsar et al. | The effects of argan oil in second-degree burn wound healing in rats | |
US9370541B2 (en) | Extract of the above-ground portions of gynandropsis gynandra or cleome gynandra, and cosmetic, dermatological or pharmaceutical compositions including same | |
KR20200088074A (ko) | 병풀 추출물 및 개양귀비 추출물을 포함하는 피부 외용제 조성물 | |
KR20110046624A (ko) | 사향쥐에서 얻은 사향추출물과 생약추출물을 함유하는 노화방지 복합 한방조성물 | |
JP5645344B2 (ja) | 外用剤組成物 | |
KR102214985B1 (ko) | 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물 | |
KR20210018388A (ko) | 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물 | |
KR101347910B1 (ko) | 생강 초임계 추출물 및 발효 미나리 박 추출물을 함유하는 식품 조성물, 화장료 조성물 및 약학 조성물 | |
CN112386655A (zh) | 大白蝴蝶兰萃取物用于制备抗醣化与改善皮肤外观的组合物的用途 | |
KR102272237B1 (ko) | 천연물을 포함하는 아토피성 피부 개선 및 피부 보습용 조성물 | |
JP2013014627A (ja) | ヘパリン結合性上皮成長因子様成長因子(hb−egf)生成促進剤 | |
KR102565684B1 (ko) | 민들레 추출물, 비타민 및 펩타이드를 유효성분으로 포함하는 여드름 개선용 화장료 조성물 | |
KR102676799B1 (ko) | 천연 복합 추출물 함유 피부 개선용 외용제 조성물 | |
KR102098964B1 (ko) | 신나무 추출물을 함유하는 탈모 질환의 예방, 치료 또는 개선용 조성물 | |
KR102471051B1 (ko) | 천연 소재를 이용한 홍조 및 아토피 예방 및 완화용 조성물 및 이를 포함하는 화장료 | |
KR102090040B1 (ko) | 신나무 추출물을 함유하는 세포 사멸 억제 활성을 가진 조성물 | |
US20240156716A1 (en) | Cosmetic use of a solanum lycopersicum fruit (tomato) skin extract | |
US20230092216A1 (en) | Active principle comprising a particular extract of punica granatum and uses for preventing and/or treating acne | |
WO2024012787A1 (en) | Composition comprising an extract of jasminum sambac and use thereof | |
JP7402478B2 (ja) | 神経成長因子発現抑制剤およびセマフォリン3a発現促進剤 | |
JP2009215272A (ja) | 肌荒れ改善皮膚外用剤 | |
JP2021195305A (ja) | 老化細胞の排除促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150123 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20150331 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151120 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160222 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20160606 |